It's not market cap for outfits that have the market cap less than a billion dollars!! It's how solidly and fast they build up the market cap!! With 26M+ short volume, do you have any idea how the confidence in Geron has eroded? And which outfit in the entire spectrum of all US small biotech companies pay $6M annual compensation to supervise no product and just a staff of 21!! Don't you think greed has occupied the mindset of Geron's CEO, not what is best for shareholders waiting to see return on their investment for two decades?!! I hope the bozo do not waste the money the company receives from JNJ!!
It is being done by Janssen and Tefferi; the bozos at Geron are incapable of doing that!! They are looking for a mom-and-pop outfit so that they can have something to do to justify their enormous compensation!!
That doesn't seem to be the primary reason. Yes, there must be some of that; but, the consistent better performance of AST and its low trading volume along with the massive short volume (26m+) of GERN doesn't support your view. I am just looking for real reasons. Of course, it looks like that there is less of a competition in the regeneration area now than in the field of Oncology; but the potential for side-effects and the long cycle of licensing (due to long-time observational requirement by the FDA) in the case of regeneration case should make it less attractive for WS!! I can't think of anything else but the Scarlett-Huh effect for the lack enthusiasm for Geron. Their stupidity of returning the $25M grant from CERN with heavy penalty and selling off the stem-cell portfolio dirt-cheap (far less than the money that was dumped in developing the technology - some $400M!!) showed their lack of foresight. These two bozos, in my view, are not fit for the rewards they are getting for screwing up!!
beachcomber, if so, JNJ wouldn't bet a billion dollars for it!! IMET is so far the only drug that has shown to attain CRs and PRs from a deadly hematologic cancer for late-stage patients. And, Tefferi/Mayo are involced too!! Are you influenced by the Jakafi lobby, like that Jackaxxxsxxxs from SA?!!
Asteria is doing consistently better than Geron despite the facts that it doesn't have any cash, JNJ-type contract or even a Ph 2 product like Geron? My guess is that the Trading/investor community doesn't like or trust Scarlett-Huh team as much as Dr. West. Am I wrong?
The cockroaches want your shares cheap and hoping enough number of fools out there will selloff. Some of them must be paid agents of WS crooks. Your summary is excellent and truthful.
Serious side effect (since the injected RPE cells stayed locally and apparently do not go into the main blood stream. This may be what the investigators look for in the about to be completed Ph 1 trials.
The final completion is in September.;i.e., with the sufficient cash the company already has in hand, I think the AMD Ph 2 must be ready to go, soon followed by the SMD trial. In the mean time, per the earlier announcement, expedited/accelerated approval will be considered and, most likely, will be approved since there were no serious side effect as observed through Ph 1 and also as it's " first, of kind" and "unmet need" situations. The company haslready announced that it is ready to meet its commercial need for the RPE cells needed for commercial treatment once license is granted. Of course, the company will have to seek collaboration with a major pharma for marketing, distribution and administrative help. But, having a breakthrough product and the huge market for SMD and AMD, that should not be a problem. Thus, I expect the company to look for such a partnership some time later next year when needed Ph 2 results will be available and the accelerated approval is in sight. You can disagree with me; but, to me, the future seems to be very good for Ocata. Perhaps better than that for Geron.
For those who look for good investment sometime down the road. The primary completion date for the on-going AMD/SMD trials is in end of August, which should be followed by an announcement for the Ph 2 for the AMD trial and the pivotal trial for the SMD soon. Later or simultaneous, I expect, announcement of possibility for the accelerated approval. Therefore, this time for low SP may soon be gone and the SP will at least go back to &6 level and higher. Your choice!! My expectation is it will.
If Geron's current CEO and most of its board members are expelled and replaced with people having better foresight and are sharper, I think the SP will jump high as institutional investors plunge in and the shorts start covering. The problem is not what is going on at the trial front, it's the stupid management that doesn't inspire optimism to institutional guys..
eoi, you are right; but, it appears, as Scarlett announced some time back, that the company IS looking for acquiring a compatible product or an outfit. I think it is best for the company to go after the Patent 615, and, hence, get Gryaznov on board. Perhaps that is what JNJ also wishes so that it can absorb Geron ultimately into its Janssen subsidiary. I hope Scarlett and HUh looks for such a step and not foolishly buy an unknown and questionable product or outfit.
If he made right decisions and if he is such a great guy, why is the Street and institutions not jumping in this stock and why the short volume is still stubbornly unchanged after almost a year since the JNJ deal is announced? Do you have answers to that? It is YOUR perception that he is great, not mine and many others'!! Just open your eyes and give credence to what others have to say!!
Greg, the deal can be a mixture of cash and securities. JNJ may also participate in financing if they are allowed a stake, which is more likely. I think the latter may be in the plan and Tefferi may also have blessed such a deal, if any. The problem is that the Geron management doesn't give any clue to its shareholders and that, I suspect, is because the bozos at Geron may be looking at their gain rather than the shareholders. Scarlett's greed for $6M compensation from an outfit with a staff of only 21 and not a penny yet in profit is indicative of what these guys may have in their mind. And, I think that may also be the worry of institutional investors who watch much more closely than TomDicken&Harrys like us.
Who is the bozo who keeps marking downthumbs for all certain posts (except the one by IrishTrader!) without understanding the content of the posts?!! Must be a disgruntled idiot!!
You are missing an important distinction here between solid-tumor cancers and hematologic cancers. IMET is effective primarily in the latter, not in the former. That shows that the treatment for the two types is not the same. Why?!!
Also, your contention that GERN SP is falling due to this Mayo research is utterly senseless, first because the Mayo research is not yet sent for licensing that takes years (it is still in its infancy) and secondly because it's due to the WS fear that the bozos at Geron may misuse the JNJ money in acquisition of a worthless product or outfit. The Street is waiting to hear from the Geron management about their plan to do so and so far there is no word. Perhaps the Street doesn't trust Scarlett-Huh team to handle any potential growth of the company since they screwed up the stem-cell deal and also the ET/PV trials, besides many other missteps.
Earfool, the urgent need is not just based on Tefferi's work!! It is based on the current practice. Tefferi's statement above doesn't include the fact that the stem-cell treatment does have several serious potential side effects and do not succeed in most cases. This is what I learned from my recent visit to Sloan Kettering in Manhattan. Yes, the need for IMET to go in the market is urgent and I am glad that it is being taken over fully by Janssen from the hands of the bozos at Geron.
for Geron, if it doesn't want to merge with JNJ, is to buy the outfit where Gryaznov currently works and then pour money it gets from JNJ in further development of Patent 615. Of course, the board will have to fire Scarlett and replace him with another sharp guy and assign Gryaznov the position of Chief Scientific Officer. This will make not only JNJ happy but also the Wall Sttreet and, also, the staff.